SyntekaBio

SyntekaBio OCF Margin

The Operating Cash Flow Margin of SyntekaBio (226330.KQ) as of Nov 20, 2026 is -310.56 %. In the previous year, Operating Cash Flow Margin was -8,693.11 % — a change of -96.43% (higher).

OCF Margin

-310.56 %

YoY

-96.43%

Last updated:

Operating Cash Flow Margin of SyntekaBio is 2025 -310.56 % . Operating Cash Flow Margin of SyntekaBio was 2024 -8,693.11 % . It decreases by -96.43% higher compared to the previous year.

The SyntekaBio OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-825.59 KRW
Jan 1, 2019
-711.05 KRW
Jan 1, 2020
-765.65 KRW
Jan 1, 2021
-1,907.56 KRW
Jan 1, 2022
-3,488.16 KRW
Jan 1, 2023
-6,545.92 KRW
Jan 1, 2024
-8,693.11 KRW
Jan 1, 2025
-310.56 KRW
The SyntekaBio OCF Margin history
YEAROCF MarginYoY
-310.56 %-96.43%
-8,693.11 %+32.80%
-6,545.92 %+87.66%
-3,488.16 %+82.86%
-1,907.56 %+149.14%
-765.65 %+7.68%
-711.05 %-13.87%
-825.59 %-85.57%
-5,721.33 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

Operating Cash Flow Margin of SyntekaBio is -310.56 % in 2025.

Operating Cash Flow Margin of SyntekaBio changed from -8,693.11 % to -310.56 %, representing a -96.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's SyntekaBio with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — SyntekaBio

All Key Metrics — SyntekaBio